CGT is an advanced carrier genetic test, which determines whether a couple are carriers of genetic mutations that could be transmitted to their children.
CGT uses Next-Generation Sequencing (NGS) to analyse a wide panel of disorders including as Cystic Fibrosis, Spinal Muscular Atrophy, Fragile-X Syndrome.
Carrier screening for donor gametes. Analysis of 7 autosomal recessive genes in sperm donors and an additional 64 X-linked genes in egg donors.
Uses NGS to analyse 519 genes associated with severe monogenic disease. CGT PLUS provides very high coverage of likely pathogenic and pathogenic mutations.
Analysis of over 2,000 genes linked to autosomal recessive and X-linked conditions. CGT EXOME is our largest carrier screen.
CGT SYNC is our unique solution when one person in a reproductive couple is a known carrier of a condition – e.g. a gamete donor is known to be a carrier. CGT SYNC provides bespoke analysis of these ‘genes of interest’ using our highest detection rate platform. Optional analysis of X-linked genes is available for female patients.
Most carriers of genetic mutations don’t have a family history of these disorders.
Is a clinically validated genetic screening test based on Next-Generation Sequencing (NGS).
Our different CGT options, tailored to each patient’s needs, make it the most complete test available.
The development of the CGT panel and the concept of comprehensive carrier screening was published in a paper by Martin et al, 2015 (Fertil Steril. 2015 Nov; 104(5):1286-93).
An analysis of preconception carrier screening and genetic matching with donor gametes was presented in an abstract by Egea et al, 2016 (Fertil Steril. 2016 Oct; e329).
Results discussing the use of carrier screening to predict the risk of disorders in the Middle-Eastern population was published as an abstract by Martin et al, 2018 (Reproductive Biomedicine Online 2018; e10)
